Innovation projects are thematically addressing the greatest societal health challenges that EIT Health intends to address with its strong network. The aim is to achieve rapid market penetration of innovative projects and services and to test and implement novel organisational provision processes in European healthcare.
The most promising ideas are developed through a multidisciplinary approach involving commercial, medical, IT and other knowledge areas into commercially viable products.
More information on iPDM-GO can be found on this website .
Diabetes mellitus represents a major and multi-dimensional challenge for humanity. In 2017, the International Diabetes Federation (IDF) estimated that there are approximately 425 million people with diabetes worldwide, and their numbers continue to rise. Therefore, providing cost-effective healthcare services tailored to the individual needs and needs of each patient is crucial.
Integrated Personalized Diabetes Management Goes Europe (iPDM-GO) is committed to solving this problem. It is a therapeutic approach that structures the treatment process, connects HCPs and patients, and integrates digital data visualization and analysis tools.
Inflammatory respiratory diseases are often diagnosed too late. Every year, respiratory diseases in the EU are responsible for 600,000 deaths and 6 million hospital visits, as well as social costs of 200 billion euros. ADAPT combines two innovations to develop a novel diagnostic kit that allows earlier and more accurate assessment of inflammatory airways disease, allowing better intervention and personalised treatment.
More than 50 million people worldwide suffer from epilepsy, making it one of the most common neurological diseases worldwide. Inaccurate seizure messages pose a major challenge to diagnosing and treating people with epilepsy. SeizeIT2 is a clinically accurate seizure detection system for people with epilepsy. This discrete portable device monitors multiple biosignals to provide a more accurate quantitative analysis of seizure activity so that people with epilepsy can receive optimised treatment for their specific condition.
More information on RealWorld4Clinic can be found on this website.
Affairs around the effectiveness, costs and market availability of drugs challenge the public confidence in the pharma industry and treatments and impacts healthcare sustainability. A key underlying cause is the limited usage of real-world information in both drug development and disease management. The shortage of real-world data limits the predictive power of clinical trials and the prevention of emergency hospitalisation in heart failure management.
RealWorld4Clinic will accelerate the market launch of MyHeartSentinel – a coin-sized medical device anchored to the fundus of the stomach. There it acquires real-life cardio-respiratory health data for exploitation in drug development and tele-cardiology. The device will be enriched by patforms for patient communication and personal data lifecycle management. RealWorld4Clinic initially targets the clinical trial market which is considered the stepping stone towards outpatient cardiological care – the RealWorld4Clinic priority market.
Drug-induced cardiac and neuronal toxicities represent major complications in the daily clinical routine and are the major cause for attrition during early drug development and post market withdrawal. Since conventional drug screenings rely on in vivo and in vitro animal models with limited translational capacity, there is an urgent need for translational assays, which are able to predict drug-induced toxicities in humans in a robust and reliable manner. The R2U Tox Assay project aims to push the limits of medical care with an innovative approach that will strengthen the healthcare system as a whole.The reliable detection of drug-induced toxicities with high-quality, ready-to-use toxicity assays at a moderate price will have an immediate impact on the patient’s health by averting potentially fatal and costly side effects.
More information on CLOSE can be found on this website.
CLOSE develops and deploys integrated solutions centred around Automated Insulin Delivery, also known as artificial pancreas (AP). Led by homecare service provider Air Liquide Healthcare and clinical contract research organisation Profil GmbH, the pan-European CLOSE consortium’s project primarily focuses on people with type 2 diabetes who are dependent on home support and suffer from comorbidities.
The AP system tailors to the needs of individuals with type 2 diabetes and is complemented with obligatory trainings of responsible healthcare professionals (“Train-the-Trainer” programme) as well as telemedical consultations. Tools for predicting treatment trajectories help to identify individuals who may particularly benefit from AP use, while performance indicators enable the evaluation of APplus use according to health economic sustainability standards.
No open calls
Do you have any questions about the current EIT Health Business Plan, the application, training or deadlines? Here you will find answers to the most important questions about your partnership with EIT Health Germany.
Innovation Projects aim at (1) the rapid market penetration of innovative products and services, and / or (2) the testing and implementation of novel organizational and healthcare delivery processes .
The maximum EIT available funding is € 1 million per year per project for a maximum duration of 36 months.
EIT Health Innovation Projects support innovative approaches in biotech, medtech and digital health that have left the phase of ground research and heading towards market approval and first customers.
As a support, we recommend making use of the CIMIT Innovation Maturity Level (IML) that measures the maturity of an innovation on four dimensions:
Ideally, you should have reached a “proof of concept” level for all four dimensions. Find further information here: https://cimit.org/documents/173804/228699/Navigating+the+HealthTech+Innovation+Cycle.pdf/2257c90b-d90b-3b78-6dc9-745db401fbc6?version=1.0
All innovation project proposals must involve Core or Associate Partners from a minimum of two CLC / InnoStars . The consortium must i nclude at least one academic and one non-academic Core or Associate Partner, ie one partner of the type “Education” or “Research” and one of any other type.
You will find a list here: www.eithealth.eu/partners
You can include External Project Partners that are not EIT Health Core or Associate Partners , eg start-ups and SMEs. The maximum funding for External Project Partners is 50,000 EUR / year.
For an EIT Health Innovation Project, you will be able to incur (pre) existing costs of the development of your innovation. These costs are called “KIC complementary activities (KCA)”. The funding ratio for 25% EIT funding (= “KIC Added-Value Activity (KAVA)”) versus 75% funding of other resources (eg other public grants, in- house resources etc.). In general, EIT accepts costs from 2015 and / or in parallel to the duration of the project.
Example: If you ask for 3M € EIT funding for your Innovation Project, you will have to demonstrate 9M € costs covered by other resources.
All proposals need to be submitted on the EIT Health online platform PLAZA: www.plaza.eithealth.eu
Please make sure that all your consortium partners have individual PLAZA accounts. You will need to add them to the work packages and budget lines in the proposal. Otherwise they will not be able to receive EIT funding.
If you are a newbie to PLAZA, please reserve at least two full days . O ne day would help to familiarize yourself with the logic of connecting work packages, costs and KPIs / outputs / deliverables. The second day will be needed to enter the details into the system.
The German CLC supports Innovation Projects from an early project ideation phase until the final submission and evaluation phase.
The support includes for example: